Immunotherapy and chemo for advanced or recurrent endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of immunotherapy (adebrelimab) with chemotherapy (carboplatin and paclitaxel), followed by adebrelimab with or without apatinib (a targeted therapy). It is for people with advanced or first-recurrent endometrial cancer who haven't had prior immunotherapy or certain targeted drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced (stage III or IV) or first-recurrent endometrial cancer (not sarcoma).
- You have not received immunotherapy (like PD-1/PD-L1 blockers) or certain targeted drugs (TKIs) before.
- You have good organ function (kidney, liver, blood counts) and a performance status that allows daily activities.
- You are willing to use effective birth control during and for 3 months after treatment (if possibly fertile).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a new drug, cadonilimab (AK104), combined with chemotherapy for women with advanced or recurrent endometrial cancer. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and a targeted drug (apatinib) for people with advanced lung neuroendocrine tumors that have not been treated before. The goal is to see if this combination can shrink or slow the growth of the tumor.
Hear when a new Recurrent/Metastatic Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.